Evolution of vaccines against COVID-19: From the initial strain to the Omicron variant.
Abstract
Vaccines represent one of the most impactful public health advances in human history, playing a fundamental role in reducing the transmission and, in some cases, eliminating infectious diseases. Since the sudden appearance of the SARS-CoV-2 virus and the onset of the global health emergency, several vaccines have been designed and licensed to address the COVID-19 pandemic in 185 countries around the world. It is therefore important to be aware of the different types of vaccines available and the facts regarding their efficacy and safety. The World Health Organization (WHO) reported as of November 8, 2022, 12,885,748,541 doses of COVID-19 vaccines administered worldwide, while, in Mexico, the secretary of health reported as of December 23, 2022, 227,341,091 doses of COVID-19 vaccines. As more vaccines are approved, it is important to track data on vaccination efforts in Mexico and discuss the need to incorporate effective preparedness and response mechanisms that include innovative vaccine production platforms in our country. The objective of this manuscript is to present to the reader the current vaccines approved against COVID-19, the variants of interest and concern identified by WHO, and to discuss the implications regarding the emergence of the new variants on the efficacy and safety of licensed vaccines.
Downloads
References
Mao HH, Chao S. Advances in Vaccines. Adv. Biochem. Eng. Biotechnol. 2020;171:155–88.
Pulendran B, Rappuoli R. Editorial overview: Vaccines 2020. Curr. Opin. Immunol. 2020;65:iii.
Carter PH, Berndt ER, Dimasi JA, Trusheim M. Investigating investment in biopharmaceutical R&D. Nat. Rev. Drug. Discov. 2016;15(10):673–4.
Díaz-Quiñónez JA. COVID-19 vaccines and appearance of SARS-CoV-2 variants. Reflecting on the case of Mexico. Gac. Med. Mex. 2021;157(2):119–20.
Chit A, Grootendorst P. The Effect of Government Policy on Pharmaceutical Drug Innovation [Internet]. Oxford Research Encyclopedia of Economics and Finance. Oxford University Press; 2019. [cited 2023 Feb 23]. Available from: https://doi.org/10.1093/acrefore/9780190625979.013.77
Grabowski HG, DiMasi JA, Long G. The roles of patents and research and development incentives in biopharmaceutical innovation. Health. Aff. (Millwood). 2015;34(2):302–10.
Lurie N, Saville M, Hatchett R, Halton J. Developing Covid-19 Vaccines at Pandemic Speed. N. Engl. J. Med. 2020;382(21):1969–73.
Secretaria de Salud. Informe integral de covid-19 en México [Internet]. 2022. [cited 2023 Feb 21]. Available from: https://epidemiologia.salud.gob.mx/gobmx/salud/documentos/covid19/Info-12-22-Int_COVID-19.pdf
Merhi G, Koweyes J, Salloum T, Khoury C al, Haidar S, Tokajian S. SARS-CoV-2 genomic epidemiology: data and sequencing infrastructure. Future. Microbiol. 2022;17(13):1001–7.
Statista. Coronavirus (COVID-19): las vacunas más usadas en el mundo | Statista [Internet]. 2023. [cited 2023 Feb 23]. Available from: https://es.statista.com/estadisticas/1207705/covid-19-vacunas-en-uso-en-el-mundo-por-numero-de-paises/
Organización Mundial de la Salud. COVID-19 vaccine tracker and landscape [Internet]. 2023. [cited 2023 Feb 20]. Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines
Organización Mundial de la Salud. La OMS publica su primera validación para uso en emergencias de una vacuna contra la COVID-19 y hace hincapié en la necesidad de un acceso mundial equitativo [Internet]. 2020. [cited 2023 Feb 21]. Available from: https://www.who.int/es/news/item/31-12-2020-who-issues-its-first-emergency-use-validation-for-a-covid-19-vaccine-and-emphasizes-need-for-equitable-global-access
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. 2020;383(27):2603–15.
Organización Mundial de la Salud. La OMS se incluye la vacuna de moderna contra la COVID-19 en su lista de uso en emergencias [Internet]. 2021. [cited 2023 Feb 21]. Available from: https://www.who.int/es/news/item/30-04-2021-who-lists-moderna-vaccine-for-emergency-use
Organización Mundial de la Salud. La OMS incluye en su lista de uso en emergencias dos vacunas adicionales contra la COVID-19 y aprueba su despliegue a través de COVAX [Internet]. 2021. [cited 2023 Feb 11]. Available from: https://www.who.int/es/news/item/15-02-2021-who-lists-two-additional-covid-19-vaccines-for-emergency-use-and-covax-roll-out
Organización Mundial de la Salud. Background document on the AZD1222 vaccine against COVID-19 developed by Oxford University and AstraZeneca [Internet]. 2021. [cited 2023 Feb 11]. Available from: https://www.who.int/publications/i/item/background-document-on-the-azd1222-vaccine-against-covid-19-developed-by-oxford-university-and-astrazeneca
Organización Mundial de la Salud. La OMS añade la vacuna de Janssen a la lista de herramientas eficaces y seguras contra la COVID-19 [Internet]. 2021. [cited 2023 Feb 21]. Available from: https://www.who.int/es/news/item/12-03-2021-who-adds-janssen-vaccine-to-list-of-safe-and-effective-emergency-tools-against-covid-19
Organización Mundial de la Salud. Background document on the Janssen Ad26.COV2.S (COVID-19) vaccine: Background document to the WHO Interim recommendations for use of Ad26.COV2.S (COVID-19) vaccine [Internet]. 2021. [cited 2023 Feb 11]. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE-recommendation-Ad26.COV2.S-background-2021.1
Organización Mundial de la Salud. La OMS incluye otra vacuna contra la COVID-19 en su lista de uso en emergencias y publica recomendaciones provisionales en materia de políticas [Internet]. 2021. [cited 2023 Feb 11]. Available from: https://www.who.int/es/news/item/07-05-2021-who-lists-additional-covid-19-vaccine-for-emergency-use-and-issues-interim-policy-recommendations
Organización Mundial de la Salud. Background document on the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (CNBG) [Internet]. 2021. [cited 2023 Feb 11]. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE-recommendation-COVID-19-vaccine-BIBP-background
Organización Mundial de la Salud. La OMS valida la vacuna de Sinovac contra la COVID-19 para su uso de emergencia y fórmula recomendaciones provisionales sobre las políticas que se deben adoptar [Internet]. 2021. [cited 2023 Feb 11]. Available from: https://www.who.int/es/news/item/01-06-2021-who-validates-sinovac-covid-19-vaccine-for-emergency-use-and-issues-interim-policy-recommendations
Organización Mundial de la Salud. Background document on the inactivated vaccine Sinovac-CoronaVac against COVID-19 [Internet]. 2021. [cited 2023 Feb 11]. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-Sinovac-CoronaVac-background-2021.1
Organización Mundial de la Salud. La OMS publica una lista de ocho vacunas contra la COVID-19 para uso en emergencias [Internet]. 2021. [cited 2023 Feb 11]. Available from: https://www.who.int/es/news/item/03-11-2021-who-issues-emergency-use-listing-for-eighth-covid-19-vaccine
Organización Mundial de la Salud. Background document on the Bharat Biotech BBV152 COVAXIN® (COVID-19) vaccine [Internet]. 2021. [cited 2023 Feb 11]. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE-recommendation-bbv152-covaxin-background
Organización Mundial de la Salud. La OMS incluye la novena vacuna contra la COVID-19 en la lista de uso en emergencias con el objetivo de aumentar el acceso a la vacunación en los países de ingresos bajos [Internet]. 2021. [cited 2023 Feb 11]. Available from: https://www.who.int/es/news/item/17-12-2021-who-lists-9th-covid-19-vaccine-for-emergency-use-with-aim-to-increase-access-to-vaccination-in-lower-income-countries
Organización Mundial de la Salud. Background document on the Novavax NVX-CoV2373 vaccine against COVID-19 [Internet]. 2021. [cited 2023 Feb 11]. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE-recommendation-Novavax-NVX-CoV2373-background
Richardson VL, Camacho Franco MA, Bautista Márquez A, Martínez Valdez L, Castro Ceronio LE, Cruz V, et al. Vaccine Effectiveness of CanSino (Adv5-nCoV) Coronavirus Disease 2019 (COVID-19) Vaccine Among Childcare Workers-Mexico, March-December 2021. Clin. Infect. Dis. 2022;75(Suppl 2):S167–73.
Organización Mundial de la Salud. Background document on the Cansino Ad5-nCoV-S vaccine (Convidecia ®) against COVID-19 [Internet]. 2022 [cited 2023 Feb 11]. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE-recommendation-Ad5-nCoV-Convidecia-background
Jones I, Roy P. Sputnik V COVID-19 vaccine candidate appears safe and effective. Lancet. 2021;397(10275):642–3.
Secretaria de Salud. 046. Otorga Cofepris autorización para uso de emergencia de vacuna Sputnik V | Secretaría de Salud | Gobierno | gob.mx [Internet]. 2021. [cited 2023 Feb 16]. Available from: https://www.gob.mx/salud/prensa/046-otorga-cofepris-autorizacion-para-uso-de-emergencia-de-vacuna-sputnik-v
Más-Bermejo PI, Dickinson-Meneses FO, Almenares-Rodríguez K, Sánchez-Valdés L, Guinovart-Díaz R, Vidal-Ledo M, et al. Cuban Abdala vaccine: Effectiveness in preventing severe disease and death from COVID-19 in Havana, Cuba; A cohort study. Lancet. Reg. Health. Am. 2022;16: 100366.
Secretaria de Salud. Arriba al país primer embarque de vacuna Abdala contra COVID-19 procedente de Cuba | Secretaría de Salud | Gobierno | gob.mx [Internet]. 2022. [cited 2023 Feb 16]. Available from: https://www.gob.mx/salud/prensa/arriba-al-pais-primer-embarque-de-vacuna-abdala-contra-covid-19-procedente-de-cuba?idiom=es
Consejo Nacional de Ciencia y Tecnología. Patria, la vacuna mexicana contra COVID-19, avanza para suministrarse como refuerzo | Conacyt [Internet]. 2023. [cited 2023 Feb 16]. Available from: https://conacyt.mx/patria-la-vacuna-mexicana-contra-covid-19-avanza-para-suministrarse-como-refuerzo/
Lara-Puente JH, Carreño JM, Sun W, Suárez-Martínez A, Ramírez-Martínez L, Quezada-Monroy F, et al. Safety and Immunogenicity of a Newcastle Disease Virus Vector-Based SARS-CoV-2 Vaccine Candidate, AVX/COVID-12-HEXAPRO (Patria), in Pigs. mBio. 2021;12(5):e0190821.
Mistry P, Barmania F, Mellet J, Peta K, Strydom A, Viljoen IM, et al. SARS-CoV-2 Variants, Vaccines, and Host Immunity. Front. Immunol. 2022;12: 809244.
Majumdar P, Niyogi S. SARS-CoV-2 mutations: the biological trackway towards viral fitness. Epidemiol. Infect. 2021;149:e110
Imai M, Ito M, Kiso M, Yamayoshi S, Uraki R, Fukushi S, et al. Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB. N. Engl. J. Med. 2023;388(1):89–91.
Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. N. Engl. J. Med. 2022;386(16):1532–46.
Organización Mundial de la Salud. Interim recommendations for the use of the Janssen Ad26.COV2.S (COVID-19) vaccine [Internet]. 2022. [cited 2023 Feb 18]. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE-recommendation-Ad26.COV2.S-2021.1
Organización Mundial de la Salud. Interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (CNBG), Sinopharm [Internet]. 2022. [cited 2023 Feb 18]. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE-recommendation-BIBP
Jin L, Li Z, Zhang X, Li J, Zhu F. CoronaVac: A review of efficacy, safety, and immunogenicity of the inactivated vaccine against SARS-CoV-2. Hum. Vaccin. Immunother. 2022;18(6): 2096970.
Organización Mundial de la Salud. Interim recommendations for use of the Bharat Biotech BBV152 COVAXIN® vaccine against COVID-19 [Internet]. 2022. [cited 2023 Feb 18]. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE-recommendation-bbv152-covaxin
Kanokudom S, Chansaenroj J, Suntronwong N, Assawakosri S, Yorsaeng R, Nilyanimit P, et al. Safety and immunogenicity of a third dose of COVID-19 protein subunit vaccine (CovovaxTM) after homologous and heterologous two-dose regimens. Int. J. Infect. Dis. 2023;126:64–72.
Organización Mundial de la Salud. Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac [Internet]. 2022. [cited 2023 Feb 18]. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-Sinovac-CoronaVac-2021.1
Shkoda AS, Gushchin VA, Ogarkova DA, Stavitskaya S v., Orlova OE, Kuznetsova NA, et al. Sputnik V Effectiveness against Hospitalization with COVID-19 during Omicron Dominance. Vaccines (Basel). 2022;10(6): 938.
Copyright (c) 2023 Angel Alberto Quintana Zuñiga, Daniela Mendoza Sánchez , José Alberto Díaz Quiñonez
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
